Citations

Clear

65 citation(s) found for "Smith, Stephen".

High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac, Adam , Landsburg, Daniel J. , Hughes, Mitchell E. , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie , Stepanovic, Adam , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Farooq, Umar , Saad, Mahak, Evens, Andrew M. , Pandya, Karan, Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Oh, Timothy S. , Nutsch, Heather, Rubinstein, P , Chaudhry, Amina, Zayac, Adam S , Medeiros, L Jeffrey , Kurt, Habibe , Torka, Pallawi , Sundaram, Suchitra , Smith, Stephen D , Naresh, Kikkeri N , Karimi, Yasmin H , Epperla, Narendranath , Bond, David A , Farooq, Umar , Evens, Andrew M , Naik, Seema G , Kamdar, Manali , Haverkos, Bradley M , Karmali, Reem , Oh, Timothy S , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Landsburg, Daniel J , Hu, Marie , Li, Shaoying , Girton, Mark , Medeiros, L. Jeffrey , Kurt, Habibe , Epperla, Narendranath , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | May 12, 2023 | Volume: 7 | Issue: 21 | Pages: 6381-6394

10.1182/bloodadvances.2023009731 | PMID 37171397 Get It

Abstract In this multi-institutional retrospective study, we examined the characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS)—a rare category defined by high-grade morphologic features and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements ("double hit"). Our results show that HGBL-NOS tumors are heterogeneous: 83% of patients had a germinal center B-cell immunophenotype, 37% a dual-expressor immunophenotype (MYC and BCL2 expression), 28% MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage IV disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included dose-adjusted cyclophosphamide, doxorubicin, vincristine, and etoposide, with rituximab and prednisone (DA-EPOCH-R; 43%); rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 33%); or other intensive chemotherapy programs. We found no significant differences in the rates of complete response (CR), progression-free survival (PFS), or overall survival (OS) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% and OS was 68.1%. In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase >3 × upper limit of normal, and a dual-expressor immunophenotype. Age >60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS. Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R vs R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.
An innovative systems perspective of protein-protein interactions in the physiologic T cell antigen receptor signaling network (TECH2P.929)
Neier, Steven C. , Smith, Stephen , Davis, Tessa R. , Nevala, Wendy K. , Markovic, Svetomir, Eckel‐Passow, Jeanette E. , Sciallis, Gabriel F., Wieland, Carilyn N. , Torgerson, Rochelle R. , Sinnwell, Jason P. , Enninga, Elizabeth Ann L. , Markovic, Svetomir N. , Neuhauser, Claudia , Schrum, Adam G.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 194 | Issue: 1_Supplement | Pages: 206.39-206.39

10.4049/jimmunol.194.supp.206.39 Get It

Abstract Signaling networks and the protein interactions that define them are of great interest, but techniques to assess these networks in unmanipulated primary human cells are limited. We have developed and applied a novel technological and analytical platform to measure proteins in shared complexes detected by exposed surface epitopes (PiSCES). Immunoprecipitation reactions are performed in multiplex using microsphere beads to measure 20+ proteins and 210+ distinct pair-wise protein associations that are important for T cell antigen receptor signaling. Jurkat T cells stimulated with superantigen generated an extensive PiSCES signature using this method and provided a dataset from which we optimized an analytical package. The system is currently being utilized to address the hypothesis that T cells isolated from skin lesions of autoimmune alopecia areta (AA) patients will have a unique PiSCES signature compared to those isolated from non-AA donors. To investigate this, we have isolated non-engineered primary cells from AA patient skin lesions and healthy controls, and have begun to identify differences in their PiSCES signatures, either directly after isolation or after stimulation with anti-CD3 and anti-CD28. We conclude that this novel PiSCES approach is capable of generating protein-protein interaction signatures that provide a unique view of TCR signalosome activity solicited from physiologic non-engineered primary human patient samples.
Frontline PET-Directed Therapy with Brentuximab Vedotin Plus AVD Followed By Nivolumab Consolidation in Patients with Limited Stage Hodgkin Lymphoma
Park, Steven I., Ansell, Stephen M. , Giri, Sharmila, Svoboda, Jakub , Smith, Stephen D. , Feldman, Tatyana , Budde, Elizabeth L., Ness, Andrew J, Choi, Yunsik , Bierman, Philip J., Lee, Hun Ju , Budde, Elizabeth L.

Mayo Clinic

Blood | November 29, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 1751-1752

10.1182/blood-2022-159258 Get It

A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).
Ansell, Stephen M. , Friedberg, Jonathan W. , Marolleau, Jean Pierre, Smith, Stephen D. , Fagerberg, Jan, Armand, Philippe , Zinzani, Pier Luigi , Bosch, Francesc , Arcaini, Luca , García‐Sánz, Ramón , Gopal, Ajay K. , Grande, Carlos , Merryman, Reid W. , Pinto, Antonio , Villasboas, José C. , Wallace, Danielle , Magalhaes, Joao Gamelas

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: TPS7586-TPS7586

10.1200/jco.2022.40.16_suppl.tps7586 Get It

TPS7586 Background: EO2463 is a therapeutic vaccine designed to activate existing commensal bacteria-specific memory T cells that cross-react with B cell markers in order to drive anti-tumor immune activity against B-cell malignancies. The four microbial-derived, synthetically produced peptides contained in EO2463 (OMP72, OMP64, OMP65, and OMP66), correspond to cytotoxic CD8 T cell HLA-A2 restricted epitopes, and exhibit molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), respectively. In pre-clinical models, these peptides can generate strong immune responses and specifically stimulate cross-reactive cytotoxic CD8 T cells to recognize the chosen B cell targets. EO2463 also contains a CD4 helper peptide referred to as universal cancer peptide 2, derived from the human telomerase reverse transcriptase catalytic subunit. The present study is a first-in-human clinical trial of this microbiome-derived peptide therapeutic cancer vaccine approach in patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL). Methods: This four-cohort phase 1/2 trial will investigate EO2463 monotherapy, and combinations of EO2463/lenalidomide (EL), EO2463/rituximab (ER), and EO2463/lenalidomide/rituximab (ER2), for treatment of patients with FL and MZL. Cohort 1 is a safety lead-in dose-finding in patients with relapsed/refractory (RR) disease, with a 3-by-3 design to establish the recommended phase 2 dose (RP2D) for EO2463 monotherapy and to confirm the safety of the RP2D for combination schedules of EL, and ER2. After the recommended EO2463 monotherapy dose is established, cohorts 2, 3, and 4 will open to accrual. Cohort 2 will investigate EO2463 monotherapy in patients with newly diagnosed FL/MZL who are not in need of treatment; cohort 3 will investigate EO2463 monotherapy, followed by ER in patients with limited tumor burden who need treatment, and cohort 4 will further investigate EL, followed by ER2 in the RR setting. EO2463 will be administered SC 4 times at 2-week intervals, followed by continued booster administrations every 4 weeks for 9 (Cohorts 2 and 3) or 12 (Cohorts 1 and 4) months. Inclusion/exclusion criteria, and the design and schedule of the intense immune and safety monitoring will be presented. The safety lead-in dose-finding is currently ongoing, and no safety concerns have been observed thus far. Clinical trial information: NCT04669171.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Chang, Julie , Christian, Beth , Advani, Ranjana H. , Bartlett, Nancy L. , Vos, Sven de , Dholaria, Bhagirathbhai , Fakhri, Bita , Fayad, Luis , Glenn, Martha, Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Krivacic, Susan, LaCasce, Ann S. , Narkhede, Mayur , Rabinovitch, Rachel , Roberts, Kenneth B. , Smith, Stephen D. , Svoboda, Jakub , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Dholaria, Bhagirathbhai R , Bartlett, Nancy L , Advani, Ranjana H , Fakhri, Bita , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Budde, Lihua E. , Caimi, Paolo F. , Habermann, Thomas M. , Hsi, Eric D. , Hu, Boyu , Kelsey, Chris R. , Khan, Nadia , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 15, 2021 | Volume: 19 | Issue: 11 | Pages: 1218-1230

10.6004/jnccn.2021.0054 | PMID 34781267 Get It

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody–drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1–mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
Imaging of the Primary Visual Pathway based on Visual Deficits
Patel, Swapnil C., Kessler, Alex , Bhatt, Alok A. , Bhatt, Alok A , Smith, Stephen M.

Mayo Clinic

Journal of Clinical Imaging Science | April 7, 2021 | Volume: 11 | Issue: No issue available | Pages: 19

10.25259/jcis_12_2021 | PMID 33880244 Get It

Vision loss can occur due to a variety of etiologies along the primary visual pathway. Understanding the anatomic organization of the visual pathway, which spans the globe to the occipital cortex, can help tailor neuroimaging to identify the cause of visual dysfunction. In this review, relevant anatomy and optimization of computed tomography and magnetic resonance imaging techniques will be described. This will be followed by a discussion of imaging findings related to pathologies at each functional anatomic level.
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
Redd, Robert , Nishihori, Taiga , Nieto, Yago , Darrah, Justin , Rao, Uttam K. , Byrne, Michael , Bond, David A. , Maddocks, Kami J. , Spinner, Michael A. , Advani, Ranjana H. , Ballard, Hatcher J. , Svoboda, Jakub , Singh, Anurag K. , Modi, Dipenkumar , Ramchandren, Radhakrishnan , Cohen, Jonathon B. , Frigault, Matthew J. , Chen, Yi‐Bin , Serritella, Anthony V. , Kline, J., Ansell, Stephen M. , Nathan, Sunita , Rahimian, Maryam, Shah, Mansi , David, Kevin A. , Park, Steven , Beaven, Anne , Habib, Alma , Bachanová, Veronika , Nakhoda, Shazia , Lynch, Ryan C. , Smith, Stephen D. , Ho, Vincent T. , LaCasce, Ann S. , Armand, Philippe , Herrera, Alex F. , Redd, Robert , Bachanova, Veronika , Nishihori, Taiga , Nieto, Yago , Advani, Ranjana H , Park, Steven I , Bond, David A , Merryman, Reid W. , Chavez, Julio C , McGuirk, Joseph P. , Romancik, Jason T. , Joyce, Robin , Khan, Nadia

Mayo Clinic

Blood Advances | March 12, 2021 | Volume: 5 | Issue: 6 | Pages: 1648-1659

10.1182/bloodadvances.2020003556 | PMID 33710337 Get It

Abstract Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy, we hypothesized that anti-PD-1 therapy before ASCT would result in acceptable outcomes among high-risk patients who progressed on or responded insufficiently to ≥1 salvage regimen, including chemorefractory patients who are traditionally considered poor ASCT candidates. We retrospectively identified 78 HL patients who underwent ASCT after receiving an anti-PD-1 mAb (alone or in combination) as third-line or later therapy across 22 centers. Chemorefractory disease was common, including 42 patients (54%) refractory to ≥2 consecutive systemic therapies immediately before anti-PD-1 treatment. Fifty-eight (74%) patients underwent ASCT after anti-PD-1 treatment, while 20 patients (26%) received additional therapy after PD-1 blockade and before ASCT. Patients received a median of 4 systemic therapies (range, 3-7) before ASCT, and 31 patients (41%) had a positive pre-ASCT positron emission tomography (PET) result. After a median post-ASCT follow-up of 19.6 months, the 18-month progression-free survival (PFS) and overall survival were 81% (95% CI, 69-89) and 96% (95% confidence interval [CI], 87-99), respectively. Favorable outcomes were observed for patients who were refractory to 2 consecutive therapies immediately before PD-1 blockade (18-month PFS, 78%), had a positive pre-ASCT PET (18-month PFS, 75%), or received ≥4 systemic therapies before ASCT (18-month PFS, 73%), while PD-1 nonresponders had inferior outcomes (18-month PFS, 51%). In this high-risk cohort, ASCT after anti-PD-1 therapy was associated with excellent outcomes, even among heavily pretreated, previously chemorefractory patients.
Comparison of 0/3-Hour Rapid Rule-Out Strategies Using High-Sensitivity Cardiac Troponin I in a US Emergency Department
Sandoval, Yader , Schulz, Karen , Sexter, Anne, Apple, Fred S. , Smith, Stephen W. , Apple, Fred S.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | June 19, 2020 | Volume: 13 | Issue: 7 | Pages: No page available

10.1161/circoutcomes.120.006565 | PMID 32552062 Get It